The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

BJU International - Tập 102 Số 11 - Trang 1531-1538 - 2008
Laurence Klotz1, L Boccon-Gibod2, Neal D. Shore3, Cal Andreou1, Bo‐Eric Persson4, P. Cantor4, Jens‐Kristian Jensen4, Tine Kold Olesen4, Fritz H. Schröder5
1Division of Urology, University of Toronto, ON, Division of Urology, Surrey Memorial Hospital, BC, Canada,
2CHU Hôpital Bichat-Claude Bernard, Paris, France
3Carolina Urologic Research Center, Myrtle Beach, SC USA
4Ferring Pharmaceuticals A/S, Copenhagen, Denmark, and
5Erasmus MC, Rotterdam, The Netherlands

Tóm tắt

OBJECTIVETo evaluate the efficacy and safety of degarelix, a new gonadotrophin‐releasing hormone (GnRH) antagonist (blocker), vs leuprolide for achieving and maintaining testosterone suppression in a 1‐year phase III trial involving patients with prostate cancer.PATIENTS AND METHODSIn all, 610 patients with adenocarcinoma of the prostate (any stage; median age 72 years; median testosterone 3.93 ng/mL, median prostate‐specific antigen, PSA, level 19.0 ng/mL) were randomized and received study treatment. Androgen‐deprivation therapy was indicated (neoadjuvant hormonal treatment was excluded) according to the investigator’s assessment. Three dosing regimens were evaluated: a starting dose of 240 mg of degarelix subcutaneous (s.c.) for 1 month, followed by s.c. maintenance doses of 80 mg or 160 mg monthly, or intramuscular (i.m.) leuprolide doses of 7.5 mg monthly. Therapy was maintained for the 12‐month study. Both the intent‐to‐treat (ITT) and per protocol populations were analysed.RESULTSThe primary endpoint of the trial was suppression of testosterone to ≤0.5 ng/mL at all monthly measurements from day 28 to day 364, thus defining the treatment response. This was achieved by 97.2%, 98.3% and 96.4% of patients in the degarelix 240/80 mg, degarelix 240/160 mg and leuprolide groups, respectively (ITT population). At 3 days after starting treatment, testosterone levels were ≤0.5 ng/mL in 96.1% and 95.5% of patients in the degarelix 240/80 mg and 240/160 mg groups, respectively, and in none in the leuprolide group. The median PSA levels at 14 and 28 days were significantly lower in the degarelix groups than in the leuprolide group (P < 0.001). The hormonal side‐effect profiles of the three treatment groups were similar to previously reported effects for androgen‐deprivation therapy. The s.c. degarelix injection was associated with a higher rate of injection‐site reactions than with the i.m. leuprolide injection (40% vs <1%; P < 0.001, respectively). There were additional differences between the degarelix and leuprolide groups for urinary tract infections (3% vs 9%. P < 0.01, respectively), arthralgia (4% vs 9%, P < 0.05, respectively) and chills (4% vs 0%, P < 0.01, respectively). There were no systemic allergic reactions.CONCLUSIONSDegarelix was not inferior to leuprolide at maintaining low testosterone levels over a 1‐year treatment period. Degarelix induced testosterone and PSA suppression significantly faster than leuprolide; PSA suppression was also maintained throughout the study. Degarelix represents an effective therapy for inducing and maintaining androgen deprivation for up to 1 year in patients with prostate cancer, and has a different mechanism of action from traditional GnRH agonists. Its immediate onset of action achieves a more rapid suppression of testosterone and PSA than leuprolide. Furthermore, there is no need for antiandrogen supplements to prevent the possibility of clinical ‘flare’.

Từ khóa


Tài liệu tham khảo

10.1210/jc.75.3.685

10.1056/NEJM199101103240205

Lepor H, 2005, Comparison of single‐agent androgen suppression for advanced prostate cancer, Rev Urol, 7, S3

10.1136/bmj.291.6506.1387

10.1016/S0022-5347(17)39774-4

10.1159/000472667

Heidenreich A, 2007, Guidelines on Prostate Cancer.

10.1038/sj.pcan.4500741

10.1016/j.urology.2004.07.033

10.1016/S0140-6736(01)06797-6

PlenaxisTM(abarelix for injectable suspension) Product description. Available at:http://www.fda.gov/Cder/foi/label/2003/021320lbl.pdf. Accessed 21 August 2008

National Comprehensive Cancer Network.Clinical Practice Guidelines in Oncology – Prostate Cancer V.1.2008

10.1016/j.eururo.2008.04.065

GittelmanM PommervillePJ PerssonBE JensenJ‐K OlesenTK.A 1‐year open‐label randomized phase II dose‐finding study of degarelix a novel gonadotropin‐releasing hormone (GnRH) receptor blocker in the treatment of prostate cancer in North America.J Urol2008(in press)

10.2217/14796694.2.6.677

World Medical Association.Declaration of Helsinki. Ethical principles for medical research involving human subjects. (Amended by the 52nd WMA General Assembly Edinburgh Scotland.; notes of clarification issued in 2002 and 2004) October 2000

Cancer Therapy Evaluation Program.Common Terminology Criteria for Adverse Events Version 3.0 DCTD NCI NIH DHHS March 31 2003(http://ctep.cancer.gov: August 9 2006http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed 20 August 2008

10.1016/S0022-5347(01)61831-7

10.1016/S1078-1439(00)00124-1

10.1016/j.eursup.2005.08.004

10.1185/030079906X96425

10.1016/j.juro.2007.05.129

10.1016/S0022-5347(05)64560-0

10.1002/cncr.10647

Ako D, 2006, Skin reactions to 3‐month depot type of luteinizing hormone‐releasing hormone agonist therapy, JMAJ, 49, 48

Eligard(7.5 mg). US product labelNovember 2007

Thông tin
Thông tin xuất bản

BJU International

Tập 102 Số 11

1531-1538

Thông tin tác giả